Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $226 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a price target of $226.
August 10, 2023 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals has received a reiterated 'Buy' rating from Needham analyst Ami Fadia, with a maintained price target of $226.
The reiterated 'Buy' rating and maintained price target by Needham analyst Ami Fadia indicates a positive outlook for Jazz Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100